What the FDA labels say about taking them together
Digoxin and valbenazine
Valbenazine's FDA label of April 17, 2026 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name valbenazine. The valbenazine label: “Digoxin Clinical Implication: Concomitant use of INGREZZA or INGREZZA SPRINKLE with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp). …”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the valbenazine FDA label on DailyMed (effective April 17, 2026, Neurocrine Biosciences, Inc.).
What does the digoxin label say about valbenazine?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name valbenazine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the valbenazine label say about digoxin?
Valbenazine label, drug interactionsDigoxin Clinical Implication: Concomitant use of INGREZZA or INGREZZA SPRINKLE with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp) [see Clinical Pharmacology ()]. Prevention or Management: Digoxin concentrations should be monitored when co-administering INGREZZA or INGREZZA SPRINKLE with digoxin. Increased digoxin exposure may increase the risk of exposure-related adverse reactions. Dosage adjustment of digoxin may be necessary.
Source: FDA drug label (INGREZZA), Neurocrine Biosciences, Inc., effective April 17, 2026 (SPL set 4c970164-cafb-421f-9eb5-c226ef0a3417), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Valbenazine | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $283.32 per capsule 80 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once